Pavelic K, Martinovic T, Kraljevic Pavelic S (2015) Do we understand personalized medicine
paradigm? EMBO Rep 16:133–136. doi:10.15252/embr.201439609
Perl DP (2007) The role of pathologist in translational and personalized medicine. Mt Sinai J Med
74:22–26
Pesce F, Pathan S, Schena FP (2013) From “omics” to personalized medicine. Nephrol Dial
Transplant 28:24–28
Pesch B, Br€uning T, Johnen G, Casjens S, Bonberg N et al (2014) Biomarker research with
prospective study design for the early detection of cancer. Biochim Biophys Acta 1844:
874–883
Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB et al (2002a)
Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359:572–577
Petricoin EF, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS et al (2002b) Serum proteomic
patterns for detection of prostate cancer. J Natl Cancer Inst 94:1576–1578
Pieborn M, Silvestri A, Spira A, Reeder A, Pin E, Banks S et al (2014) Pilot phase I/II personalized
therapy trial for metastatic colorectal cancer: evaluating the feasibility of protein pathway
activation mapping for stratifying patients to therapy with Imatinib and Panitumumab.
J Proteome Res 13:2846–2855
Pienaar IS, Dexter D, Burkhard P (2010) Mitochondrial proteomics as a selective tool for
unravelling Parkinson’s disease pathogenesis. Expert Rev Proteomics 7:205–226
Pivac N, Knezevic A, Gornik O, Pucic M, Igl W et al (2011) Human plasma glycome in attention
deficit hyperactivity disorder and autism spectrum disorders. Mol Cell Proteomics 10(1):
M110.004200. doi:10.101074/mcp.M110.004200
Plomp R, Hensbergen PJ, Rombouts Y, Zauner G, Dragan I et al (2014) Site-specific N-glycosyl-
ation analysis of human immunoglobulin E. J Proteome Res 13:536–546
Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A et al (1997) Mutation in the alpha-
synuclein gene identified in families with Parkinson’s disease. Science 276:2045–2047
Ponten F, Schwenk JM, Asplund A, Edquist PH (2011) The Human protein Atlas as a
proteomic resource for biomarker discovery. J Intern Med 270:428–446
Poste G (2011) Bring on the biomarkers. Nature 469:156–157
Pucic M, Knezevic A, Vidic J, Adamczyk B, Novokmet M et al (2011) High throughput isolation
and glycosylaton analysis of IgG-variability and heritability of the IgG glycome in three
isolated human populations. Mol Cell Proteomics 10(10):M111.010090. doi:10.1074/mcp.
M111.010090
Pucic-Bankovic M, Selman MHJ, Hoffmann M, Rudan I, Campbell H, Deelder AM, Lauc G,
Wuhrer M (2013) High-throughput IgG Fc N-glycosylation profiling by mass spectrometry of
glycopeptides. J Proteome Res 12:821–831
Rahbar A, Rivers R, Boja E, Kinsinger C, Mesri M et al (2011) Realizing individualized medicine:
the road to transferring proteomics from the laboratory to the clinic. Pers Med 8:45–57
Reljic Z, Zlatovic M, Savic-Radojevic A, Pekmezovic T, Djukanovic LJ et al (2014) Is increased
susceptibility to Balkan Endemic nephropathy in carriers of common GSTA1 (A/B) poly-
morphism linked with a catalytic role of GSTA1 in ocratoxin A biotransformation?
Serbian case control study andin silicoanalysis. Toxins (Basel) 6:2348–2362
Rodolfo C, Ciccosanti F, Giacomo GD, Piacentini M, Fimia GM (2010) Proteomic analysis of
mitochondrial dysfunction in neurodegenerative diseases. Expert Rev Proteomics 7:519–542
Rosenblatt A, Brinkmann RR, Liang KY, Almquist EW, Marglois RL et al (2001) Familial
influence on age of onset among siblings with Huntington disease. Am J Med Genet 105:
399–403
Rucevic M, Rosenquist T, Breen L, Cao L, Clifton J et al (2012) Proteome alternations in response
to aristolohic acids in experimental animal model. J Proteome Res 76:79–90
Sarker MMH, Zhou MC, Rameshwar P, Hanover JA (2014) Function and roles of proteins:
diabetes as a paradigm. Prog Biophys Mol Biol 114:2–7
Sauer S, Luge T (2014) Nutriproteomics – facts, concepts and perspectives. Proteomics. doi:10.
1002/pmic.201400383
216 D. Josic ́and U. Andjelkovic ́